SCHEMBL15546196

SCHEMBL15546196

COc1ccc(C(=O)c2cc(CC(=O)NC(=N)N)c(-c3ccc(Cl)cc3)s2)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.55
KMT2A Q03164 3/20 0.55
RXFP1 Q9HBX9 1/20 0.55
HPGD P15428 2/20 0.43
TP53 P04637 1/20 0.42
MDM2 Q00987 1/20 0.42
MAPT P10636 5/20 0.41
CNR1 P21554 1/20 0.40
CNR2 P34972 1/20 0.40
VNN1 O95497 1/20 0.39
OPRD1 P41143 1/20 0.39
RAB9A P51151 2/20 0.38
KDM4E B2RXH2 1/20 0.38
ALDH1A1 P00352 1/20 0.38
GAA P10253 1/20 0.38
PTGS2 P35354 2/20 0.38
POLB P06746 2/20 0.38
MALT1 Q9UDY8 1/20 0.38
ADORA1 P30542 1/20 0.38
NPC1 O15118 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL16893371 0.99 MEN1 (0.54) MEN1KMT2ARXFP1HPGDTP53
SCHEMBL15547477 0.91 KMT2A (0.48) MEN1KMT2ARXFP1HPGDMAPT
Hydrochloric Acid SCHEMBL16893531 0.90 KMT2A (0.48) MEN1KMT2ARXFP1HPGDMAPT
SCHEMBL15545760 0.89 MEN1 (0.55) MEN1KMT2ARXFP1HPGDTP53
SCHEMBL18035672 0.87 MEN1 (0.52) MEN1KMT2ARXFP1HPGDTP53
SCHEMBL15546901 0.87 MEN1 (0.59) MEN1KMT2ARXFP1HPGDTP53
SCHEMBL15545766 0.87 MEN1 (0.61) MEN1KMT2ARXFP1HPGDTP53
SCHEMBL16893486 0.85 MEN1 (0.57) MEN1KMT2ARXFP1HPGDTP53
SCHEMBL15546277 0.85 MEN1 (0.49) MEN1KMT2ARXFP1HPGDTP53
SCHEMBL18035695 0.84 MEN1 (0.53) MEN1KMT2ARXFP1HPGDTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2875010-B1 THIOPHENE DERIVATIVES USEFUL FOR THE TREATMENT OF DIABETES METABRAIN RES (FR) 2016-08-31 EP claimed
EP-2875010-A1 THIOPHENE DERIVATIVES USED IN THE TREATMENT OF DIABETES Metabrain Research (FR) 2015-05-27 EP claimed
WO-2014013181-A1 THIOPHENE DERIVATIVES USED IN THE TREATMENT OF DIABETES METABRAIN RESEARCH (FR) 2014-01-23 WO claimed
US-9777015-B2 Useful thiophene derivatives in the treatment of diabetes METABRAIN RESEARCH (FR) 2017-10-03 US disclosed
EP-2875010-B1 THIOPHENE DERIVATIVES USEFUL FOR THE TREATMENT OF DIABETES METABRAIN RES (FR) 2016-08-31 EP disclosed
EP-2875010-B1 THIOPHENE DERIVATIVES USEFUL FOR THE TREATMENT OF DIABETES METABRAIN RES (FR) 2016-08-31 EP disclosed
US-20150197530-A1 USEFUL THIOPHENE DERIVATIVES IN THE TREATMENT OF DIABETES METABRAIN RESEARCH (FR) 2015-07-16 US disclosed
EP-2875010-A1 THIOPHENE DERIVATIVES USED IN THE TREATMENT OF DIABETES Metabrain Research (FR) 2015-05-27 EP disclosed
WO-2014013181-A1 THIOPHENE DERIVATIVES USED IN THE TREATMENT OF DIABETES METABRAIN RESEARCH (FR) 2014-01-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150197530-A1 USEFUL THIOPHENE DERIVATIVES IN THE TREATMENT OF DIABETES SLC5A2, SLC5A1, TPMT MEN1 4184/4885KMT2A 4602/4885RXFP1 3837/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.